Fluoxetine Hydrochloride; Olanzapine Patent Expiration
Fluoxetine Hydrochloride; Olanzapine is Used for acute treatment of treatment-resistant depression in adults. It was first introduced by Eli Lilly And Co
Fluoxetine Hydrochloride; Olanzapine Patents
Given below is the list of patents protecting Fluoxetine Hydrochloride; Olanzapine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Symbyax | US6960577 | Combination therapy for treatment of refractory depression |
Nov 01, 2017
(Expired) | Lilly |
| Symbyax | US5945416 | Method for treating pain |
Mar 24, 2017
(Expired) | Lilly |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Fluoxetine Hydrochloride; Olanzapine's patents.
Latest Legal Activities on Fluoxetine Hydrochloride; Olanzapine's Patents
Given below is the list recent legal activities going on the following patents of Fluoxetine Hydrochloride; Olanzapine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical
| 01 Nov, 2005 | US6960577 |
| Recordation of Patent Grant Mailed Critical
| 01 Nov, 2005 | US6960577 |
| Issue Notification Mailed Critical
| 12 Oct, 2005 | US6960577 |
| Receipt into Pubs | 06 Oct, 2005 | US6960577 |
| Dispatch to FDC | 05 Oct, 2005 | US6960577 |
| Application Is Considered Ready for Issue Critical
| 13 Aug, 2005 | US6960577 |
| Issue Fee Payment Verified Critical
| 05 Jul, 2005 | US6960577 |
| Issue Fee Payment Received Critical
| 05 Jul, 2005 | US6960577 |
| Mail Examiner's Amendment | 02 Jun, 2005 | US6960577 |
| Mail Notice of Allowance Critical
| 02 Jun, 2005 | US6960577 |
Fluoxetine Hydrochloride; Olanzapine's Family Patents
